Efficacy of a new combination of a microemulsion and oral supplementation for androgenetic alopecia: an interventional multicentric study

Ital J Dermatol Venerol. 2022 Jun;157(3):254-261. doi: 10.23736/S2784-8671.21.07094-8. Epub 2022 Jan 24.

Abstract

Background: The aim of this study was to study new therapeutic options for the treatment of female and male androgenetic alopecia (AGA) and to assess the efficacy of a possible new coadjuvant oral and topical therapy, containing a complex of natural substances.

Methods: Sixty individuals affected by mild-to-moderate female and male AGA were enrolled in the study and underwent the oral and topical treatment with a microemulsion formulation for 6 months. At baseline and at 3- and 6-month follow-up, global photographs were taken and three expert operators evaluated photographs using the 7-point scale. On a subgroup of our sample, non-invasive phototrichograms with TrichoScan® HD at baseline and follow-ups were performed to collect the trichological parameters of total number of hairs, hair density/cm2, vellus hair density/cm2, terminal hair density/cm2 and hair thickness. One-way ANOVA and Unpaired Student t-test were performed to analyze the data.

Results: Using the 7-point scale, a clinically visible improvement of hair loss was observed after three and six months of treatment. A statistically significant increase of all TrichoScan® trichological parameters was observed at both 3- and 6 month-follow-up.

Conclusions: The complex of natural and active substances tested in this work showed good efficacy in improving both male and female hair loss. These new products could represent a valid alternative or coadjuvant therapy of AGA, increasing the efficacy of conventional treatments such as minoxidil or finasteride.

Publication types

  • Multicenter Study

MeSH terms

  • Alopecia* / drug therapy
  • Dietary Supplements
  • Female
  • Finasteride
  • Hair
  • Humans
  • Male
  • Minoxidil*

Substances

  • Finasteride
  • Minoxidil